Effectiveness of antipsychotic medication in people with intellectual disability and schizophrenia: a systematic review.

The aim of the present study was to determine the efficacy of any antipsychotic medication for treating people with a dual diagnosis of intellectual disability and schizophrenia. The authors performed an electronic search of Biological Abstracts, the Cochrane Schizophrenia Group's Register of trials...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Intellectual Disability Research Vol. 43; no. 2; pp. 94 - 105
Autores principales: Duggan L, Brylewski J
Formato: Journal Article
Publicado: Wiley-Blackwell Apr1999
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106050641&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 106050641
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        09642633
        EUL
      jtl: Journal of Intellectual Disability Research
      issn: 09642633
      maglogo: Y
    pubinfo:
      dt: Apr1999
      vid: 43
      iid: 2
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        106050641
        2009437862
        106050641
      ppf: 94
      ppct: 11
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Effectiveness of antipsychotic medication in people with intellectual disability and schizophrenia: a systematic review.
      aug:
        au:
          Duggan L
          Brylewski J
      sug:
      ab: The aim of the present study was to determine the efficacy of any antipsychotic medication for treating people with a dual diagnosis of intellectual disability and schizophrenia. The authors performed an electronic search of Biological Abstracts, the Cochrane Schizophrenia Group's Register of trials, the Cochrane Library, EMBASE, PsycLIT and MEDLINE. Unpublished data were sought from pharmaceutical companies. Both authors independently selected the relevant studies from the reports identified in this way. Only one relevant randomized trial was found by the searches (Foote 1958). This study included four people with a dual diagnosis of schizophrenia and intellectual disability, but results were only available for two subjects. The groups to which the other two people were allocated were unclear. Using the methods described, the reviewers found no trial evidence to guide the use of antipsychotic medication for those with both intellectual disability and schizophrenia. Until the urgent need for randomized controlled trials is met, clinical practice will continue to be guided by evidence from trials involving people with schizophrenia but without intellectual disability.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N